Aortic Stenosis / Aortic Sclerosis — Clinical Documentation Guide (2026)

🔍 Definition

Aortic stenosis (AS) is a structural heart disease characterized by narrowing of the aortic valve orifice, causing obstruction to left ventricular outflow. It is one of the most prevalent valvular heart diseases in adults, with a prevalence that increases significantly with age. According to the ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease, aortic stenosis is defined hemodynamically by a peak aortic jet velocity ≥ 2.0 m/s with a normal valve area of 3–4 cm² reduced to varying degrees depending on severity.

Aortic sclerosis is an important and distinct precursor condition defined by thickening, calcification, or fibrosis of the aortic valve leaflets without hemodynamically significant obstruction to outflow. By convention, aortic sclerosis does not produce a transvalvular gradient exceeding 10 mmHg and aortic jet velocity remains < 2.0 m/s. It affects approximately 25–30% of adults over age 65 and represents an independent marker of increased cardiovascular risk. Approximately 1–2% of aortic sclerosis cases progress to hemodynamically significant aortic stenosis per year, as documented in longitudinal studies referenced by the American Heart Association.

The coding distinction is clinically critical: aortic sclerosis without obstruction is typically coded to I35.8 (Other nonrheumatic disorders of aortic valve) or managed under an observation/screening Z-code framework, whereas any degree of hemodynamic obstruction (gradient > 10 mmHg; jet velocity ≥ 2.0 m/s) establishes true stenosis and warrants an AS code.

🗂️ Alternative Terminology

The following table maps formal diagnostic terms to the clinical, lay, and colloquial language commonly encountered in chart documentation. Coders and CDI specialists should recognize all variants to ensure accurate code assignment.

🩺 Signs & Symptoms

Aortic stenosis classically presents with the triad of angina, syncope, and heart failure (dyspnea). Symptom onset marks a critical prognostic threshold — untreated symptomatic severe AS carries an average survival of 2–3 years. According to UpToDate: Clinical manifestations and diagnosis of aortic stenosis in adults, key findings include:

• Angina pectoris — exertional chest pain from subendocardial ischemia due to increased oxygen demand from hypertrophied myocardium; average survival 5 years after onset
• Syncope / presyncope — exertional dizziness or loss of consciousness from inability to augment cardiac output; average survival 3 years after onset
• Heart failure / dyspnea — exertional dyspnea, orthopnea, PND due to diastolic and eventually systolic dysfunction; average survival 1–2 years after onset
• Auscultation — harsh, crescendo-decrescendo systolic ejection murmur at the right upper sternal border, radiating to the carotids; paradoxical splitting of S2; diminished or absent A2; S4 gallop
• Pulsus parvus et tardus — weak, delayed carotid upstroke on physical exam
• Reduced pulse pressure — narrow pulse pressure on BP measurement
• Signs of HF — JVD, crackles, peripheral edema, decreased exercise tolerance

Aortic sclerosis is typically asymptomatic. It may produce a soft systolic murmur (grade I–II/VI) but without hemodynamic compromise, and is often discovered incidentally on echocardiography or auscultation.

🧭 Differential Diagnosis

Accurate differential diagnosis is essential to ensure appropriate ICD-10-CM code assignment. The following conditions may mimic, co-exist with, or be confused with aortic stenosis in clinical documentation.

📋 Clinical Indicators for Coders/CDI

The following clinical indicators should prompt code assignment or a CDI query when found in chart documentation, echocardiographic reports, operative notes, or discharge summaries.

🦴 Anatomy & Pathophysiology

The aortic valve is a semilunar valve consisting of three cusps (left, right, and non-coronary) positioned at the junction of the left ventricular outflow tract (LVOT) and the ascending aorta. Its normal open area is approximately 3.0–4.0 cm². It opens during systole to permit blood ejection from the LV and closes during diastole to prevent regurgitation.

Pathophysiologic Cascade in Aortic Stenosis

1. Valve calcification / fibrosis — In degenerative (senile) AS, the process begins with lipid accumulation, inflammation, and calcification of the valve leaflets — a process akin to atherosclerosis. Risk factors mirror those of coronary artery disease: hypertension, hyperlipidemia, diabetes, age, male sex, and smoking, as described in AHA/ACC 2014 VHD Guideline (updated).
2. Progressive narrowing — As calcific deposits accumulate, leaflet mobility decreases, orifice area reduces, and a transvalvular pressure gradient develops. The LV must generate higher systolic pressure to maintain forward output.
3. Compensatory LV hypertrophy (LVH) — Chronic pressure overload triggers concentric LVH — a compensatory mechanism that initially normalizes wall stress (LaPlace's law) and preserves LVEF.
4. Diastolic dysfunction — LVH produces impaired relaxation and increased filling pressures, causing diastolic dysfunction, often before systolic dysfunction develops. This explains why many AS patients have preserved EF even in severe disease.
5. Decompensation — Eventually the LV dilates, LVEF falls, and the patient enters low-flow low-gradient AS with poor prognosis without intervention.

Aortic Sclerosis vs. Stenosis: Progression Threshold

Aortic sclerosis exists on a continuum with stenosis. The Stewart et al. NEJM/AHA study established that any Doppler peak jet velocity < 2.0 m/s across the aortic valve defines sclerosis (non-obstructive), while ≥ 2.0 m/s with a gradient > 10 mmHg defines stenosis. Annually, about 1–2% of sclerosis cases cross this threshold.

Special Populations

• Bicuspid aortic valve (BAV): Congenitally abnormal two-cusp morphology accelerates leaflet calcification — typically presenting 10–20 years earlier than tricuspid AS. BAV also confers risk of associated ascending aortopathy.
• Rheumatic AS: Caused by post-streptococcal inflammation leading to commissural fusion rather than calcification. Almost always associated with mitral valve disease. Coded separately under I06.x per ICD-10-CM convention.
• Congenital AS: Includes valvular (Q23.0), subvalvular (Q24.4), and supravalvular (Q25.3) forms; often diagnosed in childhood or early adulthood.

💊 Medication Impact / Treatment

Currently, there are no proven medical therapies that halt or reverse the progression of calcific aortic stenosis. This distinguishes AS from conditions where medications play a primary disease-modifying role. Management is therefore focused on symptom control, risk factor optimization, and surveillance — with definitive treatment being mechanical valve replacement.

Pharmacologic Considerations

• Statins: Despite the pathophysiologic similarity to atherosclerosis, randomized trials (SALTIRE, SEAS) showed no benefit of statin therapy in slowing AS progression. However, statins remain indicated for concurrent atherosclerotic cardiovascular disease (ASCVD).
• Antihypertensives: ACE inhibitors and ARBs may be used cautiously for concurrent hypertension; however, afterload reduction must be balanced against the risk of hypotension from fixed obstruction. Beta-blockers are used for rate control in concurrent AF or to manage anginal symptoms.
• Diuretics: Used for symptom management in AS complicated by heart failure (volume overload). Document carefully, as diuretic use in AS context may indicate HF as a complication — an additional reportable diagnosis.
• Anticoagulation (warfarin / NOACs): Post-SAVR with mechanical prosthesis requires lifelong anticoagulation (typically warfarin, INR 2.5–3.5). Bioprosthetic valves and post-TAVR typically use DAPT or single antiplatelet for 3–6 months then aspirin monotherapy.
• Vasodilators: Contraindicated or used with extreme caution in severe AS — nitrates and phosphodiesterase inhibitors can cause profound hypotension due to the fixed obstruction.
• Pre-procedural medications: Dexamethasone (J1100) may be used pre-TAVR to reduce inflammatory responses. Epoetin alfa (J0881) may be used pre-operatively for anemia optimization in SAVR candidates.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides